WO1997030150A3 - Molecules for the induction of immunological tolerance - Google Patents

Molecules for the induction of immunological tolerance Download PDF

Info

Publication number
WO1997030150A3
WO1997030150A3 PCT/EP1997/000777 EP9700777W WO9730150A3 WO 1997030150 A3 WO1997030150 A3 WO 1997030150A3 EP 9700777 W EP9700777 W EP 9700777W WO 9730150 A3 WO9730150 A3 WO 9730150A3
Authority
WO
WIPO (PCT)
Prior art keywords
mutated
protein
population
amino acid
acid sequence
Prior art date
Application number
PCT/EP1997/000777
Other languages
French (fr)
Other versions
WO1997030150A2 (en
Inventor
Robert F Balint
Marca Henriette Michael Wauben
Original Assignee
Pangenetics Bv
Robert F Balint
Marca Henriette Michael Wauben
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pangenetics Bv, Robert F Balint, Marca Henriette Michael Wauben filed Critical Pangenetics Bv
Priority to AU18749/97A priority Critical patent/AU1874997A/en
Publication of WO1997030150A2 publication Critical patent/WO1997030150A2/en
Publication of WO1997030150A3 publication Critical patent/WO1997030150A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Rehabilitation Therapy (AREA)
  • Ecology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to a population of protein molecules having a distribution of specific mutations in the amino acid sequence as compared to a parent protein, which population of protein molecules is obtainable by establishing the parental amino acid sequence of the protein to be mutated and deriving therefrom a parental nucleotide sequence encoding the amino acid sequence, optionally selecting sites within this parental amino acid sequence, mutation of which is more desirable or less desirable, designing overlapping oligonucleotides encoding parts of the protein and harbouring one or more codon changes as compared to the corresponding parental nucleotide sequence, composing of the overlapping oligonucleotides a population of mutated nucleotide sequences encoding mutated versions of the parent protein thus establishing a library, and expressing the mutated versions of the mutated nucleotide sequences to obtain a population of mutated proteins.
PCT/EP1997/000777 1996-02-15 1997-02-17 Molecules for the induction of immunological tolerance WO1997030150A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU18749/97A AU1874997A (en) 1996-02-15 1997-02-17 Molecules for the induction of immunological tolerance

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96200383 1996-02-15
EP96200383.6 1996-02-15

Publications (2)

Publication Number Publication Date
WO1997030150A2 WO1997030150A2 (en) 1997-08-21
WO1997030150A3 true WO1997030150A3 (en) 1997-10-09

Family

ID=8223678

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/000777 WO1997030150A2 (en) 1996-02-15 1997-02-17 Molecules for the induction of immunological tolerance

Country Status (2)

Country Link
AU (1) AU1874997A (en)
WO (1) WO1997030150A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004521618A (en) * 2000-11-16 2004-07-22 アルカベロ アクチェセルスカプ Novel mutant allergen
US20060040899A1 (en) * 2000-12-15 2006-02-23 Hassan Jomaa Medicaments containing bisphosphonic acids and derivatives thereof for preventing and treating diseases and allergies
DE60316547T2 (en) * 2002-04-17 2008-07-03 Bioren, Inc., San Carlos DOPING AT THE WALK THROUGH MUTAGENESE
AU2006259306B2 (en) * 2005-06-16 2012-02-16 Life Technologies Corporation Gene expression profiling for identification and monitoring of multiple sclerosis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995022625A1 (en) * 1994-02-17 1995-08-24 Affymax Technologies N.V. Dna mutagenesis by random fragmentation and reassembly
WO1996016085A1 (en) * 1994-11-18 1996-05-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995022625A1 (en) * 1994-02-17 1995-08-24 Affymax Technologies N.V. Dna mutagenesis by random fragmentation and reassembly
WO1996016085A1 (en) * 1994-11-18 1996-05-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ROACH, ARTHUR ET AL.: "Normal and mutant genes for the mouse myelin basic proteins", MOL. GENET. DEV. NEUROBIOL., TANIGUCHI SYMP. BRAIN SCI., 9TH (1986), 1986, pages 111 - 123, XP000672601 *
ROBERT F. BALINT ET AL.: "Antibody engineering by parsimonious mutagenesis", GENE, vol. 137, no. 1, 27 December 1993 (1993-12-27), AMSTERDAM NL, pages 109 - 118, XP002031537 *
SCHIER, ROBERT ET AL: "Identification of functional and structural amino-acid residues by parsimonious mutagenesis", GENE (1996), 169(2), 147-55 CODEN: GENED6;ISSN: 0378-1119, 1996, XP002031538 *
VIPIN KUMAR ET AL.: "Amino acid variations at a single residue in an autoimmune peptide profoundly affect its properties: T-cell activation, major histocompatibility complex binding, and an ability to block experimental allergic encephalomyelitis", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 87, no. 4, February 1990 (1990-02-01), WASHINGTON US, pages 1337 - 1341, XP000103572 *
WAUBEN, MARCA H. M. ET AL.: "Inhibition of entire myelin basic protein-induced experimental autoimmune encephalomyelitis in Lewis rats by major histocompatibility complex class II-binding competitor peptides", EUR. J. IMMUNOL., vol. 24, no. 5, 1994, pages 1053 - 1060, XP000672512 *

Also Published As

Publication number Publication date
AU1874997A (en) 1997-09-02
WO1997030150A2 (en) 1997-08-21

Similar Documents

Publication Publication Date Title
WO2002004523A3 (en) Artificial antibody polypeptides
IL131435A0 (en) In vitro peptide or protein expression library
WO1999060127A3 (en) Il-17 homologous polypeptides and therapeutic uses thereof
WO1999063088A8 (en) Membrane-bound proteins and nucleic acids encoding the same
WO1999061469A3 (en) Prostate growth-associated membrane proteins
WO1999028462A3 (en) Polypeptides and nucleic acids encoding the same
WO1998021343A8 (en) Genes encoding telomerase proteins
WO2001007611A3 (en) Novel polynucleotides and method for the use thereof
WO2000037638A3 (en) Methods and compositions for inhibiting neoplastic cell growth
MX9606013A (en) Phosphonyldipeptides useful in the treatment of cardiovascular diseases.
WO2001002588A3 (en) Generation of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests
WO1997008314A3 (en) Telomere repeat binding factor and diagnostic and therapeutic use thereof
WO2000006726A3 (en) Delta-related polypeptides
WO1995006735A3 (en) Nucleotide sequences for novel protein tyrosine phosphatases
WO1998021333A3 (en) Nucleic acid encoding schwannomin-binding-proteins and products related thereto
WO2000026244A3 (en) A novel tumor necrosis factor family member, drl, and related compositions and methods
CA2336261A1 (en) Cyclin e2 genes and proteins
WO1997030150A3 (en) Molecules for the induction of immunological tolerance
WO2002016611A3 (en) Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
WO1997015584A3 (en) Use of linalool synthase in genetic engineering of scent production
WO2000032778A3 (en) Methods and compositions for inhibiting neoplastic cell growth
WO2000039297A3 (en) Il-1 related polypeptides
WO2000031253A3 (en) Mutation of the parkin gene, compositions, methods and uses
KR100515858B1 (en) PRO617 Polypeptides
EP1241179A3 (en) Human cornichon-like protein and nucleic acids encoding it

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97529014

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase